NASDAQ:MNTA Momenta Pharmaceuticals (MNTA) Stock Price, News & Analysis → Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (From Paradigm Press) (Ad) Free MNTA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$52.48▼$52.4850-Day Range$52.26▼$52.4952-Week Range$12.21▼$52.53VolumeN/AAverage Volume1.94 million shsMarket Capitalization$6.25 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Momenta Pharmaceuticals alerts: Email Address Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… About Momenta Pharmaceuticals Stock (NASDAQ:MNTA)Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy. The company's biosimilar programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M710, a biosimilar of EYLEA for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME), and diabetic retinopathy in patients with DME. Its complex generics programs include Enoxaparin sodium injection, a generic version of LOVENOX that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing forms of multiple sclerosis; and GLATOPA, a generic version of three-times-weekly COPAXONE. The company has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.Read More Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… MNTA Stock News HeadlinesFebruary 28, 2023 | thestreet.comGenoptix, Momenta Shares Headed for GainsMay 25, 2022 | msn.comJohnson & Johnson, Momenta Pharma file lawsuit against Natco, Mylan in USMay 1, 2022 | thestreet.comEastman Kodak, Rambus: After-Hours TradingAugust 3, 2021 | nasdaq.comMomenta Pharmaceuticals, Inc. Common Stock (MNTA)See More Headlines Receive MNTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Momenta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/10/2020Today6/15/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:MNTA CUSIP60877T10 CIK1235010 Webwww.momentapharma.com Phone617-491-9700FaxN/AEmployees131Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-290,050,000.00 Net Margins-757.61% Pretax MarginN/A Return on Equity-61.44% Return on Assets-45.28% Debt Debt-to-Equity RatioN/A Current Ratio6.38 Quick Ratio6.38 Sales & Book Value Annual Sales$23.87 million Price / Sales261.69 Cash FlowN/A Price / Cash FlowN/A Book Value$4.59 per share Price / Book11.43Miscellaneous Outstanding Shares119,029,000Free FloatN/AMarket Cap$6.25 billion OptionableOptionable Beta1.71 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesMr. Craig A. Wheeler (Age 59)Pres, CEO & Exec. Director Dr. Ganesh Venkataraman Kaundinya (Age 52)Co-Founder & Consultant Dr. Santiago Arroyo (Age 59)Chief Medical Officer & Sr. VP of Devel. Mr. Bruce A. Leicher (Age 63)Consultant Mr. Scott M. StorerConsultantKey CompetitorsTwist BioscienceNASDAQ:TWSTTeva Pharmaceutical IndustriesNYSE:TEVAAlnylam PharmaceuticalsNASDAQ:ALNYBioMarin PharmaceuticalNASDAQ:BMRNNeurocrine BiosciencesNASDAQ:NBIXView All Competitors MNTA Stock Analysis - Frequently Asked Questions How were Momenta Pharmaceuticals' earnings last quarter? Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) issued its earnings results on Monday, August, 10th. The biotechnology company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.42) by $0.06. The biotechnology company earned $6.61 million during the quarter, compared to analyst estimates of $5.84 million. Momenta Pharmaceuticals had a negative net margin of 757.61% and a negative trailing twelve-month return on equity of 61.44%. What other stocks do shareholders of Momenta Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Momenta Pharmaceuticals investors own include Exelixis (EXEL), Novavax (NVAX), Gilead Sciences (GILD), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Pfizer (PFE), ACADIA Pharmaceuticals (ACAD), ImmunoGen (IMGN) and CRISPR Therapeutics (CRSP). This page (NASDAQ:MNTA) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Momenta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Momenta Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.